FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer ByRyan ScottNovember 13th 2025
Experts Highlight Notable Advances in Colorectal Cancer at 2025 ESMO ByDr. Joshua K. SabariNovember 13th 2025